Abstract
<div>Abstract<p><b>Purpose:</b> Targeted therapies are regarded as promising approaches to increase 5-year survival rate of head and neck squamous cell carcinoma (HNSCC) patients.</p><p><b>Experimental design:</b> For the selection of carcinoma-specific peptides membrane proteome of HNO97 tumor cells fractionated by the ProteomeLab PF2D system and corresponding HNO97 cells were deployed for an alternating biopanning using a sunflower trypsin inhibitor1–based phage display (SFTI8Ph) library. Stability, binding properties and affinity of novel candidates were assessed <i>in vitro</i> using radio-HPLC, binding experiments and surface plasmon resonance assay (SPR), respectively. Subsequently, the affinity of the peptide was verified <i>in situ</i> by using peptide histochemistry, <i>in vitro</i> using flow cytometry, and <i>in vivo</i> by positron emissions tomography (PET/CT).</p><p><b>Results:</b> We identified a novel ITGα<sub>v</sub>β<sub>6</sub> binding peptide (SFITGv6) containing the amino acid sequence FRGDLMQL. SFITGv6 provides stability over a period of 24 hours and demonstrates high affinity (<i>K</i><sub>D</sub> = 14.8 nmol/L) for ITGα<sub>v</sub>β<sub>6</sub>. In HNO97 cells, a maximal uptake and internalization of up to 37.3% and 37.5%, respectively, was measured. Small-animal PET imaging and biodistribution studies of HNO97 xenografted Balb/c nu/nu mice showed tumor-specific accumulation of <sup>68</sup>Ga- and <sup>177</sup>Lu-labeled DOTA-SFITGv6, respectively, 30 to 60 minutes after injection. Moreover, peptide histochemistry revealed a strong and homogenous binding of biotin-labeled SFITGv6 to HNSCC tumors and breast- and lung cancer-derived brain metastases. Finally, first PET/CT scans of HNSCC and NSCLC patients displayed SFITGv6 accumulation specifically in tumors, but not in inflammatory lesions.</p><p><b>Conclusions:</b> Thus, SFITGv6 represents a novel powerful tracer for imaging and possibly for endoradiotherapy of ITGα<sub>v</sub>β<sub>6</sub>-positive carcinoma. <i>Clin Cancer Res; 23(15); 4170–80. ©2017 AACR</i>.</p></div>
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
